The prognosis of contrast toxicity is benign, with severe adverse events occurring less than 1% of the time. CIN has beenÂ documented to occur much more frequently in the range of 10%, but recent meta-analyses have brought this into question. Overall, the benefits of contrast agent administration for diagnostic purposes are considered to outweigh the infrequent complication of toxicity substantially.